ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

GLUE Monte Rosa Therapeutics Inc

5.65
0.05 (0.89%)
Fuera de horario
Última actualización: 15:02:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Monte Rosa Therapeutics Inc GLUE NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.05 0.89% 5.65 15:02:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.82 5.645 5.85 5.65 5.60
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202415:01GLOBEMonte Rosa Therapeutics Announces the Departure of Owen..
14/3/202406:00GLOBEMonte Rosa Therapeutics Announces Fourth Quarter and Full..
11/3/202406:00GLOBEMonte Rosa Therapeutics Announces Initiation of IND Enabling..
31/1/202406:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
08/1/202406:47EDGAR2Form 8-K - Current report
08/1/202406:15GLOBEMonte Rosa Therapeutics Provides Corporate Update and Key..
04/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202406:00GLOBEMonte Rosa Therapeutics to Present at the 42nd Annual J.P...
21/11/202306:00GLOBEMonte Rosa Therapeutics to Present at Piper Sandler..
09/11/202306:27EDGAR2Form 8-K - Current report
09/11/202306:00GLOBEMonte Rosa Therapeutics Announces Third Quarter 2023..
07/11/202309:00GLOBEMonte Rosa Therapeutics Presents Preclinical Data at ACR..
27/10/202306:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
26/10/202316:01EDGAR2Form 8-K - Current report
26/10/202315:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/10/202315:30GLOBEMonte Rosa Therapeutics Announces $25 Million Registered..
17/10/202306:55EDGAR2Form 8-K - Current report
17/10/202306:00GLOBEMonte Rosa Therapeutics Announces Interim PK/PD and Clinical..
18/8/202315:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
15/8/202316:16EDGAR2Form 144 - Report of proposed sale of securities
10/8/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:19EDGAR2Form 8-K - Current report
10/8/202306:15GLOBEMonte Rosa Therapeutics Announces Second Quarter 2023..
26/7/202306:53EDGAR2Form 8-K - Current report
26/7/202306:30GLOBEMonte Rosa Therapeutics Appoints Dr. Anthony M. Manning to..
30/5/202315:30GLOBEMonte Rosa Therapeutics to Present at Upcoming Investor and..
23/5/202306:30GLOBEMonte Rosa Therapeutics Advances Second Development..
11/5/202306:30GLOBEMonte Rosa Therapeutics Announces First Quarter 2023..

Su Consulta Reciente

Delayed Upgrade Clock